Research Analysts Set Expectations for Hologic Q1 Earnings

Hologic, Inc. (NASDAQ:HOLX) – Equities research analysts at Leerink Partnrs lowered their Q1 2025 EPS estimates for Hologic in a research report issued to clients and investors on Tuesday, November 5th. Leerink Partnrs analyst P. Souda now expects that the medical equipment provider will earn $1.02 per share for the quarter, down from their previous estimate of $1.03. The consensus estimate for Hologic’s current full-year earnings is $4.36 per share. Leerink Partnrs also issued estimates for Hologic’s Q3 2025 earnings at $1.08 EPS and FY2026 earnings at $4.74 EPS.

Hologic (NASDAQ:HOLX) last announced its earnings results on Monday, November 4th. The medical equipment provider reported $1.01 earnings per share for the quarter, meeting the consensus estimate of $1.01. Hologic had a return on equity of 20.11% and a net margin of 19.59%. The company had revenue of $987.90 million for the quarter, compared to the consensus estimate of $978.25 million. During the same period last year, the business posted $0.89 EPS. The company’s revenue was up 4.5% on a year-over-year basis.

HOLX has been the subject of a number of other research reports. Needham & Company LLC restated a “buy” rating and issued a $90.00 price objective on shares of Hologic in a research report on Tuesday, October 15th. Royal Bank of Canada raised their target price on Hologic from $86.00 to $89.00 and gave the company a “sector perform” rating in a report on Tuesday. Evercore ISI upped their price target on shares of Hologic from $78.00 to $82.00 and gave the stock an “in-line” rating in a research note on Tuesday, October 1st. Mizuho reduced their price objective on shares of Hologic from $90.00 to $87.00 and set an “outperform” rating for the company in a research note on Tuesday. Finally, Leerink Partners lowered their target price on shares of Hologic from $95.00 to $90.00 and set an “outperform” rating on the stock in a research report on Tuesday, October 8th. Six investment analysts have rated the stock with a hold rating and eight have assigned a buy rating to the stock. Based on data from MarketBeat.com, Hologic presently has a consensus rating of “Moderate Buy” and a consensus target price of $89.25.

Hologic Stock Down 1.5 %

Shares of Hologic stock opened at $79.29 on Wednesday. The company has a market cap of $18.42 billion, a P/E ratio of 23.81, a PEG ratio of 3.03 and a beta of 0.98. The firm has a fifty day moving average of $81.02 and a two-hundred day moving average of $78.13. The company has a debt-to-equity ratio of 0.51, a quick ratio of 3.32 and a current ratio of 3.99. Hologic has a one year low of $66.93 and a one year high of $84.67.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Price T Rowe Associates Inc. MD lifted its stake in shares of Hologic by 77.7% during the first quarter. Price T Rowe Associates Inc. MD now owns 6,297,197 shares of the medical equipment provider’s stock valued at $490,931,000 after buying an additional 2,753,016 shares during the period. Swedbank AB acquired a new position in Hologic in the 1st quarter valued at $120,827,000. Black Creek Investment Management Inc. lifted its stake in shares of Hologic by 60.9% during the 2nd quarter. Black Creek Investment Management Inc. now owns 2,338,970 shares of the medical equipment provider’s stock worth $173,669,000 after purchasing an additional 885,524 shares during the period. Mackenzie Financial Corp boosted its holdings in shares of Hologic by 1,023.3% during the second quarter. Mackenzie Financial Corp now owns 895,699 shares of the medical equipment provider’s stock worth $66,506,000 after purchasing an additional 815,960 shares during the last quarter. Finally, Marshall Wace LLP purchased a new stake in shares of Hologic in the second quarter valued at $39,427,000. 94.73% of the stock is currently owned by hedge funds and other institutional investors.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.